Gastric remnant cancer: a comprehensive narrative review from carcinogenesis to treatment

José Darío  Portillo-Miño; Sandra Cifuentes; Javier Morales; Melissa Bastidas; William Otero; Paulo Pimentel de Assumpção; Gonzalo Latorre; Megan Neumann; Arnoldo Riquelme

doi:10.47892/rgp.2025.453.1943

Autores/as

José Darío Portillo-Miño Grupo de Investigacion en Enfermedades Infecciosas y Cancer (GINFYCA), Centro de Investigaciones Clínicas, Fundacion Hospital San Pedro. Pasto, Nariño. Colombia; Grupo Colombiano de Investigacion en Helicobacter pylori, Bogotá, Colombia. https://orcid.org/0000-0003-4858-9400
Sandra Cifuentes Grupo de Investigacion en Enfermedades Infecciosas y Cancer (GINFYCA), Centro de Investigaciones Clínicas, Fundacion Hospital San Pedro. Pasto, Nariño. Colombia; Grupo Colombiano de Investigacion en Helicobacter pylori, Bogotá, Colombia; Gastroenterology and Digestive Endoscopy Unit, Fundación Hospital San Pedro, Pasto, Nariño. Colombia. https://orcid.org/0000-0001-5114-6083
Javier Morales Grupo de Investigacion en Enfermedades Infecciosas y Cancer (GINFYCA), Centro de Investigaciones Clínicas, Fundacion Hospital San Pedro. Pasto, Nariño. Colombia; Oncological Surgery Service, Unidad Funcional del Cuidado Integral del Cáncer del Adulto (UFCA), Fundación Hospital San Pedro, Pasto, Nariño. Colombia. https://orcid.org/0009-0004-3022-8599
Melissa Bastidas Grupo Colombiano de Investigacion en Helicobacter pylori, Bogotá, Colombia. https://orcid.org/0000-0002-9830-1383
William Otero Grupo Colombiano de Investigacion en Helicobacter pylori, Bogotá, Colombia; Department of Gastroenterology, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá. Colombia; Department of Gastroenterology, Hospital Universitario Nacional de Colombia, Bogotá. Colombia. https://orcid.org/0000-0002-6825-9014
Paulo Pimentel de Assumpção Oncology Research Center, Federal University of Pará, Pará. Brazil. https://orcid.org/0000-0003-3846-8445
Gonzalo Latorre Department of Gastroenterology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago. Chile. https://orcid.org/0009-0000-2311-8747
Megan Neumann División of Surgery, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. https://orcid.org/0009-0005-0303-5828
Arnoldo Riquelme Department of Gastroenterology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago. Chile; Centro para la Prevencion y el Control del Cancer (CECAN), Santiago. Chile. https://orcid.org/0000-0002-8259-8960

DOI:

https://doi.org/10.47892/rgp.2025.453.1943

Palabras clave:

Metachronous gastric cancer, remnant gastric cancer, gastric stump, H. pylori infection, precancerous lesions

Resumen

Gastric remnant cancer is cancer secondary to partial gastrectomy after five years. Peculiarities due to the gastrectomy status may influence this type of GC. Modifications in the gastric microbiome, luminal pH, dietary habits, increased bile reflux, and Epstein-Barr virus infection, together with the traditional GC risk factors, cooperate to increase the risk of cancer in the remnant stomach. H. pylori infection has been widely associated with GC, and its role in the pathogenesis of the remnant stomach, as well as the preventive effect of its eradication after gastrectomy, are issues of great scientific interest. Bariatric surgery is another condition potentially related to increased GC risk and challenges to its diagnosis. In this scenario, this article aims to review the current evidence of the fundamental aspects involved in developing the gastric remnant cancer

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Citas

Hirata Y, Noorani A, Song S, Wang L, Ajani JA. Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nat Rev Clin Oncol. 2023;20:453-469. doi: 10.1038/s41571- 023-00767-w.

Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167-92.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209- 249.

Ohira M, Toyokawa T, Sakurai K, Kubo N, Tanaka H, Muguruma K, et al. Current status in remnant gastric cancer after distal gastrectomy. World J Gastroenterol. 2016;22(8):2424-33.

Asaka M, Kato M, Graham DY. Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med. 2010;49(7):633-6.

Park YE, Kim SW. Clinicopathologic features of remnant gastric cancer after curative distal gastrectomy according to previous reconstruction method: a retrospective cohort study. World J Surg Oncol. 2019;17(1):203.

Hanyu T, Wakai A, Ishikawa T, Ichikawa H, Kameyama H, Wakai T. Carcinoma in the Remnant Stomach During Long-Term Follow-up After Distal Gastrectomy for Gastric Cancer: Analysis of Cumulative Incidence and Associated Risk Factors. World J Surg. 2018;42(3):782-7.

Lagergren J, Lindam A, Mason RM. Gastric stump cancer after distal gastrectomy for benign gastric ulcer in a populationbased study. Int J Cancer. 2012;131(6):E1048-1052.

Di Leo A, Pedrazzani C, Bencivenga M, Coniglio A, Rosa F, Morgani P, et al. Gastric stump cancer after distal gastrectomy for benign disease: clinicopathological features and surgical outcomes. Ann Surg Oncol. 2014;21(8):2594-600.

Ishida M, Kuroda S, Choda Y, Otsuka S, Ueyama S, Tanaka N, et al. Incidence of Metachronous Remnant Gastric Cancer after Proximal Gastrectomy with the Double-flap Technique (rD-FLAP-rGC Study): A Multicenter, Retrospective Study. Ann Surg Oncol. 2023;30(4):2307-16.

Irino T, Hiki N, Ohashi M, Nunobe S, Tokunaga M, Sano T, et al. Characteristics of gastric stump cancer: A single hospital retrospective analysis of 262 patients. Surgery. 2016;159(6):1539-47.

Sinning C, Schaefer N, Standop J, Hirner A, Wolff M. Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment. Eur J Surg Oncol. 2007;33(2):133-9.

Mezhir JJ, Gonen M, Ammori JB, Strong VE, Brennan MF, Coit DG. Treatment and outcome of patients with gastric remnant cancer after resection for peptic ulcer disease. Ann Surg Oncol. 2011;18(3):670-6.

Ma FH, Liu H, Ma S, Li Y, Tian YT. Current controversies in treating remnant gastric cancer: Are minimally invasive approaches feasible? World J Clin Cases. 2019;7(21):3384-93.

Komatsu S, Ichikawa D, Okamoto K, Ikoma D, Tsujiura M, Nishimura Y, et al. Progression of remnant gastric cancer is associated with duration of follow-up following distal gastrectomy. World J Gastroenterol. 2012;18(22):2832-6.

Fukui Y, Shinohara H. ASO Author Reflections: Endoscopic Management Will Be an Effective Treatment Option for Early Remnant Gastric Cancer, Similar to Primary Gastric Cancer. Ann Surg Oncol. 2018;25(Suppl 3):743-4.

Barakat M, Seif M, Abdelfatah MM, Ofosu A, Carr-Locke DL, Othman MO. Endoscopic submucosal dissection for early neoplastic lesions in the surgically altered stomach: a systematic review and meta-analysis. Surg Endosc. 2019;33(8):2381-95.

ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc. 2015;82(1):1-8.

Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet. 1975;2(7924):58-60.

Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 2009;15(1):1-16.

Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52(24):6735-40.

Kim SB, Lee SH, Bae SI, Jeong YH, Sohn SH, Kim KO, et al. Association between Helicobacter pylori status and metachronous gastric cancer after endoscopic resection. World J Gastroenterol. 2016;22(44):9794-802.

Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, etal. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med. 2018;378(12):1085-95.

Ramos MFKP, Pereira MA, Dias AR, Dantas ACB, Szor DJ, Ribeiro Jr U, et al. Remnant gastric cancer: An ordinary primary adenocarcinoma or a tumor with its own pattern? World J Gastrointest Surg. 2 2021;13(4):366-78.

Kondo K. Duodenogastric reflux and gastric stump carcinoma. Gastric Cancer. 2002;5(1):16-22.

Kaminishi M, Shimizu N, Shimoyama S, Yamaguchi H, Tsuji E, Aoki F, et al. Denervation promotes the development of cancerrelated lesions in the gastric remnant. J Clin Gastroenterol. 1997;25 Suppl 1:S129-134.

Wroblewski LE PRJ. Helicobacter pylori in gastric carcinogenesis: mechanisms. Gastroenterol Clin North Am. 2013;42:285-98.

Kondo K, Kojima H, Akiyama S, Ito K, Takagi H. Pathogenesis of adenocarcinoma induced by gastrojejunostomy in Wistar rats: role of duodenogastric reflux. Carcinogenesis. 1995;16(8):1747-51.

Abe S, Oda I, Minagawa T, Sekiguchi M, Nonaka S, Suzuki H, et al. Metachronous Gastric Cancer Following Curative Endoscopic Resection of Early Gastric Cancer. Clin Endosc. 2018;51(3):253-9.

Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338-49.

Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9(1):19.

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635-48.

Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264-79.

Petrara MR, Freguja R, Gianesin K, Zanchetta M, De Rossi A. Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front Microbiol. 2013;4:311.

El-Sharkawy A, Al Zaidan L, Malki A. Epstein–Barr VirusAssociated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis. Front Oncol. 2018;8:265.

Rani A, Jakhmola S, Karnati S, Parmar HS, Chandra Jha H. Potential entry receptors for human γ-herpesvirus into epithelial cells: A plausible therapeutic target for viral infections. Tumour Virus Res. 2021;12:200227.

Iizasa H, Kartika AV, Fekadu S, Okada S, Onomura D, Wadi AFAA, et al. Development of Epstein-Barr virus-associated gastric cancer: Infection, inflammation, and oncogenesis. World J Gastroenterol. 2022;28(44):6249-57.

Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Metaanalysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137(3):824-33.

Riquelme A, Abnet CC, Goodman KJ, Piazuelo MB, Ruiz-Garcia E, de Assumpção PP, et al. Recommendations for gastric cancer prevention and control in the Americas. Lancet Reg Health Am. 2023;27:100608.

Herrero R, Carvajal LJ, Camargo MC, Riquelme A, Porras C, Ortiz AP, et al. Latin American and the Caribbean Code Against Cancer 1st edition: Infections and cancer. Cancer Epidemiol. 2023;86 Suppl 1:102435.

Mori G, Nakajima T, Asada K, Shimazu T, Yamamichi N, Maekita T, et al. Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful Helicobacter pylori eradication: results of a large-scale, multicenter cohort study in Japan. Gastric Cancer. 2016;19(3):911-8.

Mak TK, Guan B, Peng J, Chong TH, Wang C, Huang S, et al. Prevalence and characteristics of gastric remnant cancer: A systematic review and meta-analysis. Asian J Surg. 2021;44(1):11-7.

Safatle-Ribeiro AV, Ribeiro Júnior U, Sakai P, Iriya K, Ishioka S, Gama-Rodrigues J. Gastric stump mucosa: is there a risk for carcinoma? Arq Gastroenterol. 2001;38(4):227-31.

Jaroenlapnopparat A, Bhatia K, Coban S. Inflammation and Gastric Cancer. Diseases. 2022;10(3):35.

Dantas ACB, Santo MA, de Cleva R, Sallum RAA, Cecconello I. Influence of obesity and bariatric surgery on gastric cancer. Cancer Biol Med. 2016;13(2):269-76.

Maehata Y, Nakamura S, Fujisawa K, Esaki M, Moriyama T, Asano K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012;75(1):39-46.

Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42 Suppl 17:21-7.

Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol. 2013;23(6 Pt B):492-501.

Ohba R, Iijima K. Pathogenesis and risk factors for gastric cancer after Helicobacter pylori eradication. World J Gastrointest Oncol. 2016;8(9):663-72.

Basso L, Gallo G, Biacchi D, Carati MV, Cavallaro G, Esposito L, et al. Role of New Anatomy, Biliopancreatic Reflux, and Helicobacter Pylori Status in Postgastrectomy Stump Cancer. J Clin Med. 2022;11(6):1498.

Miwa K, Hasegawa H, Fujimura T, Matsumoto H, Miyata R, Kosaka T, et al. Duodenal reflux through the pylorus induces gastric adenocarcinoma in the rat. Carcinogenesis. 1992;13(12):2313-6.

Powolny A, Xu J, Loo G. Deoxycholate induces DNA damage and apoptosis in human colon epithelial cells expressing either mutant or wild-type p53. Int J Biochem Cell Biol. 2001;33(2):193-203.

Busby WF, Shuker DE, Charnley G, Newberne PM, Tannenbaum SR, Wogan GN. Carcinogenicity in rats of the nitrosated bile acid conjugates N-nitrosoglycocholic acid and N-nitrosotaurocholic acid. Cancer Res. 1985;45(3):1367-71.

Xu Y, Watanabe T, Tanigawa T, Machida H, Okazaki H, Yamagami H, et al. Bile acids induce cdx2 expression through the farnesoid x receptor in gastric epithelial cells. J Clin Biochem Nutr. 2010;46(1):81-6.

Nozaki I, Nasu J, Kubo Y, Tanada M, Nishimura R, Kurita A. Risk factors for metachronous gastric cancer in the remnant stomach after early cancer surgery. World J Surg. 2010;34(7):1548-54.

Lundegårdh G, Adami HO, Helmick C, Zack M, Meirik O. Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med. 1988;319(4):195-200.

Fukuhara K, Osugi H, Takada N, Takemura M, Higashino M, Kinoshita H. Reconstructive procedure after distal gastrectomy for gastric cancer that best prevents duodenogastroesophageal reflux. World J Surg. 2002;26(12):1452-7.

Collard JM, Romagnoli R. Roux-en-Y jejunal loop and bile reflux. Am J Surg. 2000;179(4):298-303.

Leivonen MK, Haglund CH, Nordling SF. Helicobacter pylori infection after partial gastrectomy for peptic ulcer and its role in relapsing disease. Eur J Gastroenterol Hepatol. 1997;9(4):371-4.

Leivonen M, Nordling S, Haglund C. Does Helicobacter pylori in the gastric stump increase the cancer risk after certain reconstruction types? Anticancer Res. 1997;17(5B):3893-6.

Lynch DA, Mapstone NP, Clarke AM, Jackson P, Dixon MF, Quirke P, et al. Cell proliferation in the gastric corpus in Helicobacter pylori associated gastritis and after gastric resection. Gut. 1995;36(3):351-3.

Usui Y, Taniyama Y, Endo M, Koyanagi YN, Kasugai Y, Oze I, et al. Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer. N Engl J Med. 2023;388(13):1181-90.

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784-9.

Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392-7.

Salama NR, Hartung ML, Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 2013;11(6):385-99.

Abe H, Murakami K, Satoh S, Sato R, Kodama M, Arita T, et al. Influence of bile reflux and Helicobacter pylori infection on gastritis in the remnant gastric mucosa after distal gastrectomy. J Gastroenterol. 2005;40(6):563-9.

Bair MJ, Wu MS, Chang WH, Shih SC, Wang TE, Chen CJ, et al. Spontaneous clearance of Helicobacter pylori colonization in patients with partial gastrectomy: correlates with operative procedures and duration after operation. J Formos Med Assoc. 2009;108(1):13-9.

Fukuhara K, Osugi H, Takada N, Takemura M, Lee S, Taguchi S, et al. Duodenogastric reflux eradicates Helicobacter pylori after distal gastrectomy. Hepatogastroenterology. 2004;51(59):1548-50.

Ansari S, Yamaoka Y. Helicobacter pylori BabA in adaptation for gastric colonization. World J Gastroenterol. 2017;23(23):4158-69.

Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019;11(11):677.

Achtman M AT, Berg DE, Ito Y, Morelli G. Recombination and clonal groupings within Helicobacter pylori from different geographical regions. Mol Microbiol. 1999;32: 459-70.

Tafreshi M, Guan J, Gorrell RJ, Chew N, Xin Y, Deswaerte V, et al. Helicobacter pylori Type IV Secretion System and Its Adhesin Subunit, CagL, Mediate Potent Inflammatory Responses in Primary Human Endothelial Cells. Front Cell Infect Microbiol. 2018;8:22.

Backert S, Haas R, Gerhard M, Naumann M. The Helicobacter pylori Type IV Secretion System Encoded by the cag Pathogenicity Island: Architecture, Function, and Signaling. Curr Top Microbiol Immunol. 2017;413:187-220.

Buß M, Tegtmeyer N, Schnieder J, Dong X, Li J, Springer TA, et al. Specific high affinity interaction of Helicobacter pylori CagL with integrin αV β6 promotes type IV secretion of CagA into human cells. FEBS J. 2019;286(20):3980-97.

Wang H, Zhao M, Shi F, Zheng S, Xiong L, Zheng L. A review of signal pathway induced by virulent protein CagA of Helicobacter pylori. Front Cell Infect Microbiol. 2023;13:1062803.

Yong X, Tang B, Li BS, Xie R, Hu CJ, Luo G, et al. Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways. Cell Commun Signal. 2015;13:30.

Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu K, et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 2022;7(1):358.

Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036.

Bravo LE, van Doom LJ, Realpe JL, Correa P. Virulenceassociated genotypes of Helicobacter pylori: do they explain the African enigma? Am J Gastroenterol. 2002;97(11):2839-42.

Piazuelo MB, Camargo MC, Mera RM, Delgado AG, Peek RM, Correa H, et al. Eosinophils and mast cells in chronic gastritis: possible implications in carcinogenesis. Hum Pathol. 2008;39(9):1360-9.

Loh JT, Shaffer CL, Piazuelo MB, Bravo LE, McClain MS, Correa P, et al. Analysis of cagA in Helicobacter pylori strains from Colombian populations with contrasting gastric cancer risk reveals a biomarker for disease severity. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2237-49.

de Sablet T, Piazuelo MB, Shaffer CL, Schneider BG, Asim M, Chaturvedi R, et al. Phylogeographic origin of Helicobacter pylori is a determinant of gastric cancer risk. Gut. 2011;60(9):1189-95.

Correa P, Piazuelo MB. Gastric cancer: The colombian enigma. Rev Colomb Gastroenterol. 2010;25(4):334-7.

Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. 1990;50(15):4737-40.

Camargo MC, Yepez MC, Ceron C, Guerrero N, Bravo LE, Correa P, et al. Age at acquisition of Helicobacter pylori infection: comparison of two areas with contrasting risk of gastric cancer. Helicobacter. 2004;9(3):262-70.

Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-9.

Giuliani A, Galati G, Demoro M, Scimò M, Pecorella I, Basso L. Screening of Helicobacter pylori infection after gastrectomy for cancer or peptic ulcer: results of a cohort study. Arch Surg. 2010;145(10):962-7.

Offerhaus GJ, Rieu PN, Jansen JB, Joosten HJ, Lamers CB. Prospective comparative study of the influence of postoperative bile reflux on gastric mucosal histology and Campylobacter pylori infection. Gut. 1989;30(11):1552-7.

Tomtitchong P, Onda M, Matsukura N, Tokunaga A, Kato S, Matsuhisa T, et al. Helicobacter pylori infection in the remnant stomach after gastrectomy: with special reference to the difference between Billroth I and II anastomoses. J Clin Gastroenterol. 1998;27 Suppl 1:S154-158.

Chan DC, Fan YM, Lin CK, Chen CJ, Chen CY, Chao YC. Rouxen-Y reconstruction after distal gastrectomy to reduce enterogastric reflux and Helicobacter pylori infection. J Gastrointest Surg. 2007;11(12):1732-40.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073-81.

Hamaguchi K, Ogawa K, Katsube T, Konno S, Aiba M. Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication. Langenbecks Arch Surg. 2004;389(2):83-91.

Onoda N, Katsuragi K, Sawada T, Maeda K, Mino A, Ohira M, et al. Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer. J Exp Clin Cancer Res. 2005;24(4):515-21.

O’Connor HJ, Dixon MF, Wyatt JI, Axon AT, Ward DC, Dewar EP, et al. Effect of duodenal ulcer surgery and enterogastric reflux on Campylobacter pyloridis. Lancet. 1986;2(8517):1178-81.

Fukuhara K, Osugi H, Takada N, Takemura M, Ohmoto Y, Kinoshita H. Quantitative determinations of duodenogastric reflux, prevalence of Helicobacter pylori infection, and concentrations of interleukin-8. World J Surg. 2003;27(5):567-70.

Cho SJ, Choi IJ, Kook MC, Yoon H, Park S, Kim CG, et al. Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. Aliment Pharmacol Ther. 2013;38(5):477-89.

Sacks BC, Mattar SG, Qureshi FG, Eid GM, Collins JL, BarinasMitchell EJ, et al. Incidence of marginal ulcers and the use of absorbable anastomotic sutures in laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2006;2(1):11-6.

Chung WC, Jeon EJ, Lee KM, Paik CN, Jung SH, Oh JH, et al. Incidence and clinical features of endoscopic ulcers developing after gastrectomy. World J Gastroenterol. 2012;18(25):3260-6.

Salame M, Jawhar N, Belluzzi A, Al-Kordi M, Storm AC, Abu Dayyeh BK, et al. Marginal Ulcers after Roux-en-Y Gastric Bypass: Etiology, Diagnosis, and Management. J Clin Med. 2023;12(13):4336.

Jung HJ, Lee JH, Ryu KW, Lee JY, Kim CG, Choi IJ, et al. The influence of reconstruction methods on food retention phenomenon in the remnant stomach after a subtotal gastrectomy. J Surg Oncol. 2008;98(1):11-4.

Guadagni S, Walters CL, Smith PL, Verzaro R, Valenti M, Reed PI. N-nitroso compounds in the gastric juice of normal controls, patients with partial gastrectomies, and gastric cancer patients. J Surg Oncol. 1996;63(4):226-33.

Butcher LD, den Hartog G, Ernst PB, Crowe SE. Oxidative Stress Resulting From Helicobacter pylori Infection Contributes to Gastric Carcinogenesis. Cell Mol Gastroenterol Hepatol. 2017;3(3):316-22.

Bechi P, Amorosi A, Mazzanti R, Romagnoli P, Tonelli L. Gastric histology and fasting bile reflux after partial gastrectomy. Gastroenterology. 1987;93(2):335-43.

Fukuhara K, Osugi H, Takada N, Takemura M, Lee S, Taguchi S, et al. Correlation between duodenogastric reflux and remnant gastritis after distal gastrectomy. Hepatogastroenterology. 2004;51(58):1241-4.

Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;gutjnl-2022-327745.

El-Nakeep S, Kasi A. Linitis Plastica. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [citado 21 de febrero de 2024]. Disponible en: https://www.ncbi.nlm.nih. gov/books/NBK563294/

Choe Y, Kim BW, Kim TH, Chung JW, Kim J, Na SY, et al. The optimal interval of surveillance gastroscopy after endoscopic resection for gastric neoplasia: a multicenter cohort study. Surg Endosc. 2023;37(10):7556-62.

Kwon YH, Kim N, Lee JY, Choi YJ, Yoon K, Yoon H, et al. The diagnostic validity of the (13)c-urea breath test in the gastrectomized patients: single tertiary center retrospective cohort study. J Cancer Prev. 2014;19(4):309-17.

Danesh J, Appleby P, Peto R. How often does surgery for peptic ulceration eradicate Helicobacter pylori? Systematic review of 36 studies. BMJ. 1998;316(7133):746-7.

Akbari M, Tabrizi R, Kardeh S, Lankarani KB. Gastric cancer in patients with gastric atrophy and intestinal metaplasia: A systematic review and meta-analysis. PLoS One. 2019;14(7):e0219865.

Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27(2):205-23.

Choi J, Kim SG, Yoon H, Im JP, Kim JS, Kim WH, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol. 2014;12(5):793-800.e1.

Choi IJ. Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer. Korean J Intern Med. 2013;28(5):525-37.

Lee JY, Choi IJ, Cho SJ, Kim CG, Kook MC, Lee JH, et al. Endoscopic submucosal dissection for metachronous tumor in the remnant stomach after distal gastrectomy. Surg Endosc. 2010;24(6):1360-6.

Zhao Z, Zhang R, Chen G, Nie M, Zhang F, Chen X, et al. Anti-Helicobacter pylori Treatment in Patients With Gastric Cancer After Radical Gastrectomy. JAMA Netw Open. 2024;7(3):e243812.

Wong BCY, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291(2):187-94.

Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020;7(7):CD005583.

Temido MJ, Mbanze D, Almeida N, Oliveiros B, Gravito-Soares E, Figueiredo P. Is hybrid therapy more efficient in the eradication of Helicobacter pylori infection? A systematic review and metaanalysis. Ann Clin Microbiol Antimicrob. 2023;22(1):54.

Laudanno O, Ahumaran G, Thome M, Adami P, Ustares F, Rodriguez PC, et al. Argentinean Registry on Helicobacter pylori Management: Effectiveness of First and Second-line empirical treatment. Gastroenterology. 2024;166(5 Suppl):426.

Hae Won Yoo, and Su Jin Hong. Influence of h. pylori treatment on metachronous recurrence in elderly patients after endoscopic resection of gastric cancer: a nationwide cohort study. Gastroenterology. 2024;166(5):426.

Ford AC, Yuan Y, Park JY, Forman D, Moayyedi P. Eradication Therapy to Prevent Gastric Cancer in HelicobacterpyloriPositive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies. Gastroenterology. 2025;S0016-5085(25)00041-1.

Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381(9862):205-13.

Kubota K, Shimizu N, Nozaki K, Takeshita Y, Ueda T, Imamura K, et al. Efficacy of triple therapy plus cetraxate for the Helicobacter pylori eradication in partial gastrectomy patients. Dig Dis Sci. 2005;50(5):842-6.

Bertoli Neto JL, Lourenço LG, Bertoli CF, Ulbrich FS, Sabbi AR, Bueno AG. Evaluation of the efficacy of triple therapy regimen for Helicobacter pylori eradication in gastrectomized patients with gastric adenocarcinoma. Gastric Cancer. 2006;9(4):291-4.

Sheu BS, Yang HB, Wang YL, Kao AW, Chuang CH, Lin PW, et al. Stool antigen assay to screen H. pylori infection and to assess the success of 3-Day and 7-Day eradication therapy in the patients with partial gastrectomy. Helicobacter. 2002;7(3):199-204.

Yue H, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2018;21(4):579-87.

Kato S MN, Matsuda N, Tsukada K, Naito Z, Tajiri T. Helicobacter pylori eradication therapy modulates acidity and interleukin-1β mRNA levels in un-operated stomach and in remnant stomach after gastrectomy in gastric cancer patients. Aliment Pharmacol Ther. 2006;24 Suppl 4:278-284.

Kim HJ, Kim N, Park JH, Choi S, Shin CM, Lee OJ. Helicobacter pylori Eradication Induced Constant Decrease in Interleukin1B Expression over More Than 5 Years in Patients with Gastric Cancer and Dysplasia. Gut Liver. 2020;14(6):735-45.

Ekström AM, Held M, Hansson LE, Engstrand L, Nyrén O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology. 2001;121(4):784-91.